Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose versus two-dose antenatal anti-D prophylaxis in RhD-negative pregnancy
ACTRN12613000661774Phase 4Completed
- Sponsor
- Associate Professor Craig E Pennell
- Start
- May 2013
- Modality
- Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of anti-D immunoglobulin in Erythroblastosis fetalis (HDFN) (2 arms), sponsored by Associate Professor Craig E Pennell. Primary endpoints: Detectability of anti-D at delivery and Proportion of women receiving doses at correct gestation. Started May 2013; status: completed.
02
Drugs
anti-D immunoglobulin
03
Conditions
Erythroblastosis fetalis (HDFN)
Beyond the preview
Go deeper on ACTRN12613000661774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12613000661774.